Cargando…
International Prognostic Index-Based Immune Prognostic Model for Diffuse Large B-Cell Lymphoma
BACKGROUND: The International Prognostic Index (IPI) is widely used to discriminate the prognosis of patients with diffuse large B-cell lymphoma (DLBCL). However, there is a significant need to identify novel valuable biomarkers in the context of targeted therapy, such as immune checkpoint blockade...
Autores principales: | Mu, Shidai, Shi, Deyao, Ai, Lisha, Fan, Fengjuan, Peng, Fei, Sun, Chunyan, Hu, Yu |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8569825/ https://www.ncbi.nlm.nih.gov/pubmed/34745101 http://dx.doi.org/10.3389/fimmu.2021.732006 |
Ejemplares similares
-
Prognostic role of neutrophil-to-lymphocyte ratio in diffuse large B cell lymphoma patients: an updated dose–response meta-analysis
por: Mu, Shidai, et al.
Publicado: (2018) -
Prognostic role of neutrophil–lymphocyte ratio in multiple myeloma: a dose–response meta-analysis
por: Mu, Shidai, et al.
Publicado: (2018) -
Prognostic and clinicopathological significance of long noncoding RNA HOXA11-AS expression in human solid tumors: a meta-analysis
por: Mu, Shidai, et al.
Publicado: (2018) -
Reassessment of the prognostic value of the International Prognostic Index and the revised International Prognostic Index in patients with diffuse large B-cell lymphoma: A multicentre study
por: HUANG, HONG-HUI, et al.
Publicado: (2012) -
Proposed New Dynamic Prognostic Index for Diffuse Large B-Cell Lymphoma: International Metabolic Prognostic Index
por: Mikhaeel, N. George, et al.
Publicado: (2022)